医学
血管生成
免疫疗法
免疫系统
免疫
临床试验
癌症研究
免疫检查点
免疫学
内科学
作者
Zowi R. Huinen,Elisabeth J. M. Huijbers,Judy R. van Beijnum,Patrycja Nowak-Śliwińska,Arjan W. Griffioen
标识
DOI:10.1038/s41571-021-00496-y
摘要
Immune checkpoint inhibitors have revolutionized medical oncology, although currently only a subset of patients has a response to such treatment. A compelling body of evidence indicates that anti-angiogenic therapy has the capacity to ameliorate antitumour immunity owing to the inhibition of various immunosuppressive features of angiogenesis. Hence, combinations of anti-angiogenic agents and immunotherapy are currently being tested in >90 clinical trials and 5 such combinations have been approved by the FDA in the past few years. In this Perspective, we describe how the angiogenesis-induced endothelial immune cell barrier hampers antitumour immunity and the role of endothelial cell anergy as the vascular counterpart of immune checkpoints. We review the antitumour immunity-promoting effects of anti-angiogenic agents and provide an update on the current clinical successes achieved when these agents are combined with immune checkpoint inhibitors. Finally, we propose that anti-angiogenic agents are immunotherapies - and vice versa - and discuss future research priorities.
科研通智能强力驱动
Strongly Powered by AbleSci AI